Regeneron Pharmaceuticals
REGN
620 hedge funds and large institutions have $24.9B invested in Regeneron Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 223 increasing their positions, 211 reducing their positions, and 97 closing their positions.
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
6% more repeat investments, than reductions
Existing positions increased: 223 | Existing positions reduced: 211
0.7% more ownership
Funds ownership: 67.76% → 68.47% (+0.7%)
3% less funds holding
Funds holding: 639 → 620 (-19)
7% less capital invested
Capital invested by funds: $26.9B → $24.9B (-$1.94B)
14% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 97
31% less call options, than puts
Call options by funds: $594M | Put options by funds: $861M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
+$591M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$250M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$213M |
| 4 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$136M |
| 5 |
Two Sigma Advisers
New York
|
+$111M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$418M |
| 2 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
-$296M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$155M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$98.2M |
| 5 |
Millennium Management
New York
|
-$96M |
REGN Hedge Fund Activity: Q1 2018 in Review
620 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2018, worth a combined $24.9B — down 7.2% from $26.9B a quarter earlier.
Sellers outnumbered buyers: 97 funds closed out of REGN and 83 opened new positions — a net loss of 14 holders — while 211 trimmed existing stakes and 223 added.
The largest buyer was Harris Associates, opening a new position worth an estimated $591M. The largest seller was Artisan Partners, exiting entirely with an estimated $418M sold.
- 620 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2018, down from 639 in Q4 2017.
- Funds reported $24.9B of Regeneron Pharmaceuticals stock for Q1 2018, down 7.2% quarter-over-quarter.
- 83 funds opened new Regeneron Pharmaceuticals positions in Q1 2018 and 97 closed out, a net change of -14 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2018 was Harris Associates, an estimated $591M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2018 was Artisan Partners, an estimated $418M sold.
Based on aggregated 13F filings for Q1 2018.